Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Dentsply Sirona's CFO Matthew Garth Steps Down Effective November 5, 2025

Author: Benzinga Newsdesk | November 07, 2025 04:52pm

On November 6, 2025, DENTSPLY SIRONA Inc. (the "Company") filed a Current Report on Form 8-K (the "Original Report") reporting that the Company had determined that Matthew E. Garth will no longer serve as the Executive Vice President and Chief Financial Officer of the Company effective November 5, 2025 (the "Separation Date"). This Amendment No. 1 on Form 8-K/A amends the Original Report to provide additional information regarding arrangements relating to Mr. Garth's cessation of service.


 

On November 7, 2025, the Company entered into a Separation and Release of Claims Agreement with Mr. Garth (the "Separation Agreement"), pursuant to which Mr. Garth will receive (i) separation payments totaling $1,200,000, payable in two installments of $600,000 each, (ii) an amount equal to $32,430 representing twelve months of COBRA premiums for continuation of medical, dental, and vision insurance coverage, (iii) the ability to remain eligible to earn a prorated portion (5/36ths) of the performance restricted share units originally granted to Mr. Garth on May 30, 2025, with such proration based on actual attainment of the performance criteria at the conclusion of the applicable performance period, and (iv) outplacement services for twelve months following the Separation Date. Except for the prorated performance restricted share units described above, all unvested portions of Mr. Garth's equity awards will be forfeited and canceled for no consideration. Mr. Garth's receipt of such separation payments and benefits is contingent on his timely execution and nonrevocation of a release of claims and his compliance with his post-termination obligations, including the restrictive covenants set forth in the Separation Agreement. The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Separation Agreement, which is filed as Exhibit 10.1 and incorporated herein by reference.


 

Posted In: XRAY

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist